LGALSL Human

Lectin Galactoside-Binding-Like Human Recombinant
Cat. No.
BT20384
Source
E.coli.
Synonyms
GRP, HSPC159, Galectin-related protein, Lectin galactoside-binding-like protein, LGALSL.
Appearance
Sterile Filtered colorless solution.
Purity
Greater than 90% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock
Quick Inquiry

Description

LGALSL Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 195 amino acids (1-172a.a) and having a molecular mass of 21.4kDa. LGALSL is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Product Specs

Introduction
Galectins are a family of carbohydrate-binding proteins that play a role in cell-to-cell and cell-to-matrix interactions. They are involved in various biological processes, including tumor development, RNA splicing, and programmed cell death. LGALSL, a protein related to galectins, consists of 172 amino acids and contains a galectin-like domain. However, unlike typical galectins, LGALSL is not known to bind carbohydrates due to the absence of crucial amino acid residues required for binding.
Description
Recombinant human LGALSL, expressed in E. coli, is a single polypeptide chain without any sugar modifications. It comprises 195 amino acids, including the 172 amino acids of LGALSL and a 23 amino acid His-tag at the N-terminus. The protein has a molecular weight of 21.4 kDa and is purified using specialized chromatographic methods.
Physical Appearance
A clear and colorless solution that has been sterilized by filtration.
Formulation
The LGALSL protein is provided in a solution at a concentration of 0.5 mg/ml. The solution contains 20 mM Tris-HCl buffer (pH 8.0), 0.1 M NaCl, 20% glycerol, and 1 mM DTT.
Stability
For short-term storage (up to 4 weeks), keep the protein solution at 4°C. For longer storage, freeze the solution at -20°C. Adding a carrier protein (0.1% HSA or BSA) is recommended for extended storage. Avoid repeated freezing and thawing cycles.
Purity
The purity of the protein is greater than 90%, as determined by SDS-PAGE analysis.
Synonyms
GRP, HSPC159, Galectin-related protein, Lectin galactoside-binding-like protein, LGALSL.
Source
E.coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSMAGSVAD SDAVVKLDDG HLNNSLSSPV QADVYFPRLI VPFCGHIKGG MRPGKKVLVM GIVDLNPESF AISLTCGDSE DPPADVAIEL KAVFTDRQLL RNSCISGERG EEQSAIPYFP FIPDQPFRVE ILCEHPRFRV FVDGHQLFDF YHRIQTLSAI DTIKINGDLQ ITKLG.

Product Science Overview

Discovery and Structure

LGALS3BP was first discovered in the early 1990s by two independent research groups. It was identified as a 90 kDa tumor-associated antigen recognized by SP2 monoclonal antibody in CG-5 human breast cancer cells and by L3 monoclonal antibody in Calu-1 human lung cancer cells . The protein contains one Galectin domain, but it does not appear to bind carbohydrates or lactose as the critical residues required for binding are not conserved .

Functions and Roles

LGALS3BP plays a multifunctional role in the human body. It is involved in various cellular processes, including:

  1. Cancer Progression: LGALS3BP is enriched in cancer-associated extracellular vesicles and is considered a promising candidate for targeted therapy in LGALS3BP-positive cancers . Changes in protein glycosylation associated with neoplastic transformation can result in altered glycoprotein conformation, oligomerization, and turnover, affecting cell signaling pathways related to cancer progression .

  2. Innate Immunity: The protein has intracellular activity, mainly implicated in the regulation of innate immune responses. It has been demonstrated that intracellular LGALS3BP reduces the amount of HIV Gag at the plasma membrane via interaction with vimentin and inhibits the proteolytic maturation of HIV gp160/Env . Additionally, it plays a role in the prevention and treatment of inflammatory diseases by suppressing TAK1-dependent NF-κB activation .

  3. Autophagy Regulation: Galectins, including LGALS3BP, are involved in autophagy regulation, which is crucial for maintaining intracellular homeostasis under physiological and pathological conditions . Dysregulation of autophagy is associated with various diseases, including cancer, neurodegenerative diseases, type II diabetes, and heart disease .

Clinical Implications

The abnormal expression of LGALS3BP is closely related to cancer biology, including vascular formation, cell migration, and tumor immune evasion during carcinogenesis . In most cases, the upregulated expression of LGALS3BP in the tumor microenvironment predicts a poor prognosis . Therefore, LGALS3BP has drawn particular attention in cancer research and therapy.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Category

Service

THE BIOTEK
THE BioTek is a global biotech company offering highly purified proteins for research in cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cells.
  • Contact
  • Address: 1925 E Maple Ave, El Segundo, CA 90245 United States
  • Phone : +1 201-285-7826
  • Email : info@thebiotek.com
  • Hours : Mon.-Fri. 9:00 AM - 5:00 PM
© Copyright 2024 Thebiotek. All Rights Reserved.